Theranovir - Breakthrought Solutions for Effective Therapies

Breakthrough Solutions for Effective Therapies

Oncology

Anti-Cancer Solutions Targeting metastasis, failure and drug resistance

Obesity

Preventing cancers by Treating Obesity

Viral Infection

Example : targeting adipose tissue HIV reservoir and Covid19

About us

THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patents in January 2023.

THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.

Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex

Zakia Belaid-Choucair(*) et al .Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA):

AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3293. doi:10.1158/1538-7445.AM2014-3293. * Dr. ZAKIA BELAID-SANDAL (PhD) ( Widow Choucair)

Theranovir rewards

THERANOVIR is a winner of :

Lab-SHAKER 2017 (Genopole),
Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
HEC-Challenge+ 2019 (HEC Paris),
Ilab 2020 (Ministry of education and research),
Innov’up PIA 2021 (Ile-de-France region) competitions.
NETVA Start in America 2024

Team

Operational team

Zakia BELAID-SANDAL (PhD)

Co-founder-President / CEO/CSO

17 years of experience in leading and participating in oncology programs in France and abroad

3 co-invented patents

Badia FERAZ-DUSAUTOIR (PhD)

Chief Operating Officer/COO

With 25+ years of experience (in Big Pharma) in Business Development (Due Diligence / External innovation), Preclinical & Clinical Development and Drug Discovery. International experience